| Brand Name | Tagrisso |
| Packaging Type | Bottle |
| Molecule | Osimertinib |
| Generic Name | Osimertinib |
| Manufactured By | Astrazeneca Pharma India |
| Form | Tablets |
| Country of Origin | India |
| Categories | Oncology |
Introduction to Tagrisso 80mg
Tagrisso 80mg is a targeted therapy designed to treat certain types of non-small cell lung cancer (NSCLC) that have mutations in the epidermal growth factor receptor (EGFR) gene. AstraZeneca Pharma India manufactures Tagrisso 80 mg. Tagrisso 80mg tablets contain the active component Osimertinib. EGFR is a protein that plays a key role in cell growth and division. In the case of an EGFR mutation, cancer cells can multiply uncontrollably. This tablet works by inhibiting the activity of this mutated EGFR, thereby stopping or slowing the growth of cancer cells. The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several scenarios.
Uses of Tagrisso 80mg
- As an adjuvant therapy after complete surgical removal of the tumor.
- As a first-line treatment for metastatic NSCLC (when the cancer has spread to other parts of the body).
- As a treatment for metastatic NSCLC that has worsened during or after using other similar medications.
How Tagrisso 80mg Tablet Works
Tagrisso 80mg Tablet is an anti-cancer medication that targets specific mutations in the epidermal growth factor receptor (EGFR). It works by blocking the activity of abnormal EGFR proteins, which signal cancer cells to grow and multiply. By inhibiting these signals, Tagrisso helps to slow or stop the growth and spread of cancer cells, particularly in patients with non-small cell lung cancer (NSCLC) that carry certain EGFR mutations.
Administration of Tagrisso 80mg Tablet
Take Tagrisso 80mg Tablet exactly as prescribed by the patient's doctor, in the recommended dose, and for the specified duration. Swallow the tablet whole; do not chew, crush, or break it. Tagrisso can be taken with or without food, but it is important to take it at the same time each day for the best results. Always follow the patient's doctor's instructions and recommendations for proper use.
Side Effects of Tagrisso 80 mg Tablets
- Diarrhea
- Loss of appetite
- Rash
- Inflammation of the mouth
- Risk of Infection
- Bruising and bleeding
- Sore throat or mouth ulcers
- Dry skin
- Nail toxicity
- Fatigue
- Decreased appetite
- Low blood cell counts
- Anemia
Benefits of Tagrisso 80mg Tablet in Non-Small Cell Lung Cancer (NSCLC)
Tagrisso 80mg Tablet, containing Osimertinib, is an effective treatment for certain types of EGFR-positive NSCLC. It can be used alone or in combination with other medications, depending on the specific case.
Tagrisso works by targeting and blocking proteins in cancer cells that promote cancer growth. By doing so, it can help to slow or stop the progression of advanced lung cancer. In addition to treating existing cancer, Tagrisso may be used after surgery to help prevent the cancer from returning.
Interaction of Tagrisso 80mg Tablet with other drugs
It is important to inform the patient’s healthcare specialist about all the medications you are taking before starting Tagrisso 80mg Tablet, as certain drugs can interact with it and affect its effectiveness. Some antifungal medications like ketoconazole and itraconazole may increase the risk of side effects by raising Tagrisso levels in the blood, while anticonvulsants such as phenytoin and carbamazepine can reduce their effectiveness. Antibiotics like rifampin, and proton pump inhibitors (PPIs) like omeprazole can also interfere with Tagrisso’s function. Additionally, taking blood thinners such as warfarin alongside Tagrisso may increase the risk of bleeding. Always consult a patient's doctor before starting or stopping any medication while on Tagrisso to avoid potential interactions.
Precautions while taking Tagrisso 80 mg tablets
The safety of consuming alcohol while taking Tagrisso 80mg Tablet is not established. 
Tagrisso 80mg Tablet may not be safe during pregnancy. 
This Tablet is likely unsafe during breastfeeding. Limited human data suggests that the drug may pass into breast milk and could harm the baby.
Tagrisso 80 Tablet does not usually impair a patient's ability to drive. 
This tablet is considered safe for patients with kidney disease
Tagrisso 80mg Tablet is safe for patients with liver disease. No dose adjustment is needed. Tagrisso targets non-small cell lung cancer (NSCLC) with specific EGFR mutations.
Follow your doctor’s instructions regarding any restrictions on food, beverages, or activities. In particular, avoid grapefruit and grapefruit juice, as they can interfere with how Osimertinib works.
No, Osimertinib is not a traditional chemotherapy drug. It is a targeted therapy that specifically inhibits EGFR mutations involved in the growth and spread of non-small cell lung cancer (NSCLC).
Tagrisso is available in 40 mg and 80 mg doses. The appropriate dose depends on the patient's condition and is determined by the healthcare provider.
Tagrisso has a half-life of approximately 48 hours, meaning it stays in the body for several days after the last dose.
Tagrisso is expensive due to the high cost of research, development, clinical trials, and the complex manufacturing processes involved in producing targeted therapies like Osimertinib.
Some side effects of Tagrisso may subside as your body adjusts to the medication, while others may persist. It's important to consult your healthcare provider for guidance on managing side effects.
The effectiveness of Tagrisso is monitored through regular scans, imaging tests, and assessments of cancer markers by your healthcare provider. Improvement in symptoms may also indicate that the medication is working.
The duration of Tagrisso treatment depends on how well the medication works and how well it is tolerated. Some patients take it for several months or years as long as it remains effective.
No, Tagrisso is neither chemotherapy nor immunotherapy. It is a targeted therapy specifically designed to inhibit mutated EGFR in certain types of lung cancer.
Tagrisso can remain effective for several months or even years, depending on the patient’s response and the progression of their cancer.
Tagrisso is not a cure for lung cancer, but it can significantly extend survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.
You can order Osimertinib by logging into your account on our website, adding the tablet to your cart, and proceeding to checkout. After successful payment, your order will be confirmed, and you will receive a confirmation email. You can also contact us via WhatsApp to place your order directly.
Yes, Tagrisso can interact with several drugs, including antiarrhythmics, antipsychotics, antibiotics, and supplements like St. John’s wort. These interactions may increase the risk of side effects or make Tagrisso less effective.
Yes, Tagrisso may reduce fertility in both males and females. If you're concerned about future fertility, talk to your doctor about options like sperm or egg preservation.
No, Tagrisso is not safe during pregnancy or breastfeeding. Use birth control while taking Tagrisso and for several weeks after your last dose.
